56,790 Shares in Intellia Therapeutics, Inc. $NTLA Purchased by Leonteq Securities AG

Leonteq Securities AG purchased a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 56,790 shares of the company’s stock, valued at approximately $511,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Oppenheimer & Co. Inc. grew its holdings in Intellia Therapeutics by 0.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock worth $945,000 after purchasing an additional 808 shares during the period. Comerica Bank grew its holdings in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after purchasing an additional 901 shares during the period. Federated Hermes Inc. grew its holdings in Intellia Therapeutics by 39.7% during the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after purchasing an additional 927 shares during the period. Interchange Capital Partners LLC grew its holdings in Intellia Therapeutics by 9.7% during the third quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company’s stock worth $202,000 after purchasing an additional 1,030 shares during the period. Finally, Benjamin Edwards Inc. grew its holdings in Intellia Therapeutics by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock worth $591,000 after purchasing an additional 1,126 shares during the period. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Up 1.9%

Shares of NASDAQ:NTLA opened at $12.60 on Friday. Intellia Therapeutics, Inc. has a 12-month low of $6.83 and a 12-month high of $28.25. The stock has a market cap of $1.76 billion, a PE ratio of -3.56 and a beta of 1.93. The business has a 50 day moving average of $13.53 and a 200-day moving average of $11.96.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The company had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million. During the same quarter in the previous year, the company posted ($1.10) earnings per share. Equities research analysts expect that Intellia Therapeutics, Inc. will post -3.31 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. KeyCorp set a $25.00 price target on Intellia Therapeutics in a report on Wednesday, January 28th. Wedbush restated a “neutral” rating and set a $12.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, May 12th. Citigroup restated an “outperform” rating on shares of Intellia Therapeutics in a report on Tuesday, April 28th. William Blair upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a report on Monday, March 2nd. Finally, Royal Bank Of Canada boosted their price objective on Intellia Therapeutics from $9.00 to $15.00 and gave the stock a “sector perform” rating in a report on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $20.25.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.